539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for ObeldesivirJared Pitts, John P. Bilello, Rita Humeniuk et al.|Open Forum Infectious Diseases|2023Cited by 3